Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Smith & Nephew Snats ( (SNN) ) is now available.
On August 22, 2025, Smith & Nephew plc executed a share purchase transaction as part of its remuneration policy to compensate Non-Executive Directors with shares instead of cash for part of their annual fees. This move, disclosed on August 26, 2025, aligns with the UK Market Abuse Regulation and reflects the company’s strategic approach to align director interests with shareholder value, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company that operates in the healthcare industry. It specializes in advanced wound management, orthopedics, and sports medicine, focusing on providing innovative solutions to improve patient outcomes.
Average Trading Volume: 967,587
Technical Sentiment Signal: Buy
Current Market Cap: $16.24B
See more data about SNN stock on TipRanks’ Stock Analysis page.